Ajanta Pharma Share: Q3 Results Ka Dhamaka, Par Income Tax Ka Khauf?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Ajanta Pharma Share: Q3 Results Ka Dhamaka, Par Income Tax Ka Khauf?
Overview

Ajanta Pharma ne Q3 FY2026 mein kamaal kar diya! Revenue **20%** upar gaya, **₹1,375 Cr** ho gaya aur profit bhi **18%** tez hokar **₹274 Cr** tak pahunch gaya. Sabse bada reason? US mein generics ka bheedar performace!

Yaar, Ajanta Pharma ke results toh dekhne layak hain! Is baar Q3 mein company ne zabardast performance dikhayi hai. Revenue 20% upar gaya, pichle saal ke ₹1,146 Cr se ab ₹1,375 Cr ho gaya hai. Aur Profit After Tax (PAT)? Woh bhi 18% tez ho gaya, ₹233 Cr se ₹274 Cr par pahunch gaya. EBITDA bhi 19% badh kar ₹382 Cr raha, aur margin 28% par maintain kiya hai.

Agar 9 mahine ki baat karein toh revenue 16% badh kar ₹4,031 Cr ho gaya aur PAT 14% badh kar ₹789 Cr ho gaya. Forex ka thoda loss tha ₹61 Cr, lekin adjusted EBITDA 15% growth ke saath ₹1,123 Cr raha, margin 28% par pakka. Return on Capital Employed (ROCE) 34% aur Return on Net Worth (RONW) 26% hai, matlab paisa achha use ho raha hai.

Kya chal raha hai is bheedar growth ke peeche? 🤔

Sabse bada hero raha hai US Generics segment, jisme 52% ki toofani tezi aayi hai Q3 mein, ₹399 Cr ka contribution! 9 mahine mein bhi yeh 46% badha hai. Branded Generics bhi theek-thaak chal raha hai. Bas Africa Institution segment thoda neeche gir gaya.

Lekin, yahan hai ek twist! 🚨

Abhi sab kuch itna bhi smooth nahi hai. Do badi chizein hain jo investors ko pareshan kar sakti hain:

  1. Income Tax ka search: Pichhle saal August mein Income Tax walon ne kuch jagahon par search kiya tha. Company ne bola hai ki iska asar abhi pata nahi chal paya hai ("not yet ascertainable"). Ismein kuch bhi ho sakta hai.
  2. Naye Labour Codes: November 2025 se naye labour laws aa rahe hain, jinka asar bhi company ke kharchon par pad sakta hai.

Toh bhaiyo, results toh badhiya hain, par yeh tax aur labour code wale factors ko nazarandaaz mat karna. Dekhte hain aage kya hota hai!

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.